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548Gain of 1q21 Is an Unfavorable Genetic Prognostic
Factor for Multiple Myeloma Patients Treated with
High-Dose Chemotherapy
Pavel Nemec,1,2 Zuzana Zemanova,3 Henrieta Greslikova,1,2 Kyra Michalova,3
Hana Filkova,1,2 Jana Tajtlova,3 Dana Kralova,1 Renata Kupska,1 Jan Smetana,1,2
Marta Krejci,4 Ludek Pour,4 Lenka Zahradova,4 Viera Sandecka,4 Zdenek Adam,4
Tomas Buchler,5 Ivan Spicka,6 Evzen Gregora,7 Petr Kuglik,1,2 Roman Hajek1,4The prognostic significance of 1q21 gain, del(13)(q14), del(17)(p13), t(4;14)(p16.3;q32), and t(11;14)(q13;q32)
detected by interphase fluorescein in situ hybridization (FISH) was studied in a cohort of 91 patients with
newly diagnosed multiple myeloma (MM). 1q21 gain was detected in 37 of 91 patients (40.7%). In comparison
with patients lacking 1q21 gain, patientswith 1q21 gain had significantly shorter progression-free survival (PFS)
(14.9 versus 27.4 months; P5 .044) and worse 4-year overall survival (OS) (40.1% versus 76.2% of patients;
P5\.001). PFS or OS were not influenced by the presence or absence of the other studied chromosomal
abnormalities. Although the occurrence of 1q21 gain correlated with deletion of 13q14, the presence of 1q21
gain can be considered an independent prognostic factor, as no impact of del(13)(q14) as an isolated chromo-
somal abnormality on either PFS or OS has been observed. In comparison with patients lacking 1q21 gain, pa-
tients with 1q21 gain were significantly more likely to discontinue the preplanned treatment protocol because
of disease progression or death.We conclude that 1q21 gain defines a prognostically unfavorable group ofMM
patients.
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6/j.bbmt.2009.11.025Multiple myeloma (MM) is the second most
common hematologic malignancy, representing ap-
proximately 1% of all cancer diagnoses. MM is charac-
terized by expansion and accumulation of clonal
plasma cells in the bone marrow (BM), secretion of
monoclonal immunoglobulin, and the presence of
osteolytic bone lesions. Although treatment strategies
have improved in the last decade, MM still remains an
incurable disease. High-dose chemotherapy with au-
tologous stem cell transplantation (SCT) has become
the standard of care for all eligible MM patients, and
has been shown to prolong survival [1,2]. Significant
benefits of thalidomide and bortezomib in newly diag-
nosed elderly patients have been confirmed in random-
ized trials [3,4]. Development of chromosomal
abnormalities in plasma cells plays a major role in
the disease pathogenesis. Complex numeric and struc-
tural chromosomal aberrations occur in MM. Their
identification, characterization, and the assessment of
their correlation with outcome are critical components
of the effort to individualize treatment and design low-
risk therapeutic strategies [5,6].
Biol Blood Marrow Transplant 16:548-554, 2010 549Gain of 1q21 in Multiple MyelomaGain of 1q21 is 1 of the most common chromo-
somal aberrations in MM. It is found in up to 48%
of abnormal metaphase karyotypes [7,8]. Previous
studies in MM have revealed that chromosomal gains
of 1q consistently involve the 1q21 region and can oc-
cur in the form of isochromosome, duplication, or
jumping translocation [8,9]. Using fluorescein in situ
hybridization (FISH), 1q21 gain has been detected in
36% or 43% of newly diagnosed MM patients and
has been associated with poor prognosis [10,11]. One
of the genes located at 1q21 is CKS1B, which codes
an essential cofactor for SKP2-dependent ubiquitina-
tion of p27Kip1 [12,13]. Inverse correlation between
p27 protein levels and CKS1B mRNA levels was ob-
served. CKS1B overexpression may be from increased
copy number of 1q21 [14]. However, other genes over-
expressed in this region have been reported to be asso-
ciated with poor prognosis and/or drug resistance in
MM [15]. Likewise, other chromosomal aberrations
such as deletion of 13q14 (RB1 gene), deletion of
17p13 (TP53 gene), and translocation t(4;14) (overex-
pression of FGFR3 andMMSET) have previously been
reported as negative prognostic factors either in the
presence of a single abnormality or in association
with other aberrations [6,16-20].
We have analyzed 1q21 gain status in 91 newly di-
agnosed MM patients. Our objective was to assess the
incidence of 1q21 gain, its association with other chro-
mosomal abnormalities, and to evaluate its clinical
relevance in our patients.PATIENTS, MATERIALS, AND METHODS
Patients
Clinical data of newly diagnosed MM patients regis-
tered in the CMG2002 clinical trial (EudraCTno. 2006-
001673-22) were analyzed to establish the prognostic
significance of selected chromosomal abnormalities.
The CMG2002 trial was a phase III randomized clinical
trial for newly diagnosed MM patients. Treatment in-
cluded induction chemotherapy with 4 cycles of vincris-
tine, doxorubicin, and dexamethasone (VAD), followed
by high-dose chemotherapy (melphalan [Mel] 200 mg/
m2) and autologous SCT and then randomization to ei-
ther consolidation therapy or maintenance therapy [21].
A total of 545 patients were enrolled from April 2002 to
April 2007. A total of 208 (38.2%) of themhad interphase
FISH results for standard cytogenetic factors including
del(13)(q14), del(17)(p13), and translocations t(4;14)
and t(11;14). Patient BM samples, if available, were addi-
tionally analyzed for the presence of 1q21 gain after the
publication of new data about the prognostic significance
of the abnormality in MM. Ninety-one of 208 (43.7%)
patients had available BM samples, and only this sub-
group of 91 patients with evaluable FISH for 1q21 gain
has been analyzed in this study. The median follow-upof this subgroup was 39.2 months. Clinical and biologic
characteristics of all 91 patients are summarized in Table
1 A. Twenty-four of the 91 (26%) patients were not ran-
domized because of 1 of the following: death before ran-
domization 45.8% (11/24), progression of disease before
randomization 29.2% (7/24), breach of treatment proto-
col 16.7% (4/24), or refusal of treatment by patient 8.3%
(2/24). The remaining 67 patients were randomized after
transplantation. Survival analysis calculations were done
for the 67 randomized patients together with 18 patients
excluded from treatment protocol because of progression
and/or death before randomization. Thus, a total of 85
patients were included in the survival analysis. The study
was approved by the relevant institutional review boards
and ethics committees, and all participants gave written
informed consent.cIg FISH Analysis
Interphase FISH with cytoplasmic immunoglobu-
lin light chain staining (cIg FISH) was performed as
described previously [22]. At least 50 clonal plasma
cells in each patient sample were evaluated either by
an Olympus BX61 fluorescence microscope equipped
with a Vosskuhler 1300D digital camera and an
LUCIA-KARYO/FISH/CGH imaging system (Labo-
ratory Imaging, s.r.o, Czech Republic) or an AXIO-
PLAN 2 Imaging microscope (Carl Zeiss Imaging
Solutions GmbH, Mu¨nchen, Germany) equipped
with an ISIS computer analysis system (MetaSystems
GmbH, Altlussheim, Germany). For 1q21 gain status,
1p36/1q21-specific probes from Poseidon (Kreatech
Diagnostics B.V, Amsterdam, The Netherlands) or
home-brew DNA probes were used. Bacterial artificial
chomosomes (BACs) containing 1q21 (RP11-205M9)
and a control probe 1p36 (RP11-62M23) were pur-
chased from BAC/PAC Resources (Oakland, CA,
USA). Both BACs were directly labeled by nick-trans-
lation with dUTP Spectrum-Green (3 hours) and
dUTP Spectrum-Red (4 hours) (Abbott Molecular,
Des Plaines, IL, USA). BAC clone information was ob-
tained through the UCSC (University of California,
Santa Cruz, CA, USA) genome browser and the spec-
ificity and sensitivity was extensively confirmed ac-
cording to the ACMG (American College of Medical
Genetics) recommendations (Standards and Guide-
lines for Clinical Genetic Laboratories, 2006 Edition)
at metaphase spreads and interphase nuclei from the
peripheral blood (PB) cells from donors with normal
karyotype [23,24]. If at least 3 copies of 1q21 signal
were seen in at least 20% of clonal plasma cells, it
was considered as the evidence of 1q21 gain. For
del(13)(q14) (RB1 gene), del(17)(p13) (TP53 gene), and
translocations t(4;14)(p16.3;q32) and t(11;14)(q13;q32),
commercial DNA probes were used (Abbott Molecular,
Des Plaines, IL, USA). Cutoff levels for positive results
were estimated according to European Myeloma
Table 1. Baseline Clinical and Biological Characteristics of the Analyzed MM Patient Cohort
A) B)
Characteristics All Patients
1q21 Gain
Negative
1q21 Gain
Positive P
No. of patients 91 54 (59.3%) 37 (40.6%) —
aSex
Male 55 (60.4%) 35 (64.8%) 20 (54.1%) .384
Female 36 (39.6%) 19 (35.2%) 17 (45.9%)
bAge median
(years); range
58 (33-66) 58 (39-65) 57 (33-66) .583
cIg isotype
IgG 51 (56.7%) 30 (55.6%) 21 (58.3%) .218
IgA 26 (28.9%) 17 (31.5%) 9 (25.0%)
IgM 2 (2.2%) 2 (3.7%) 0 (0.0%)
IgD 1 (1.1%) 1 (1.9%) 0 (0.0%)
Secretory IgH 9 (10.0%) 3 (5.6%) 6 (16.7%)
cISS stage (N 5 80)
I 32 (41.0%) 26 (55.3%) 6 (19.4%) .005
II 25 (32.1%) 12 (25.5%) 13 (41.9%)
III 21 (26.9%) 9 (19.1%) 12 (38.7%)
cDurie-Salmon stage (N 5 91)
I 5 (5.5%) 3 (5.6%) 2 (5.4%) .878
II 17 (18.7%) 11 (20.4%) 6 (16.2%)
III 69 (75.8%) 40 (74.1%) 29 (78.4%)
bHemoglobin (g/L) median; range 109 (73-154) 116.5 (73-154) 102 (83-147) .030
db2-microglobulin (mg/L) median; range 3.39 (1.2-35.5) 2.6 (1.2-35.5) 4.32 (1.7-20.0) .004
dAlbumin (g/L) median; range 37 (22-51) 37.1 (22-51) 35.6 (22-47) .038
dCRP (mg/L) median; range 5.1 (0.0-274.0) 4.7 (0.0-274.0) 5.8 (0.0-102.6) .065
4Calcium (mmol/l) median; range 2.38 (2.0-3.8) 2.39 (2.0-3.8) 2.35 (2.0-3.6) .539
bLDH (ukat/L) median; range 5.42 (2.0-18.3) 5.48 (2.0-15.2) 5.41 (2.1-18.3) .226
bMonoclonal Ig (g/L) median; range 36.5 (0.0-87.3) 36.0 (1.2-74.4) 37.0 (0.0-87.3) .628
Ig indicates immunoglobulin; ISS, International Staging System; MM, multiple myeloma; CRP, C-reactive protein; LDH, lactate dehydrogenase.
(A) All 91 patients. (B) Patients with/without the gain of 1q21. Statistical tests used:
aFischer test.
bt-test.
cM-L c2-test.
dMann-Whitney test.
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and 20% for the deletions and gains [25].Statistical Analysis
Outcome and maximal treatment response after
high-dose chemotherapy were assessed according to
the International Myeloma Workgroup criteria [26].
Overall response rate (ORR) comprised complete re-
sponse (CR), very good partial response (VGPR), and
partial response (PR). In univariate analysis, overall
survival (OS) and progression-free survival (PFS) dis-
tributions were estimated using the Kaplan-Meier
method, and differences between survival curves
were analyzed using the log-rank test. In multivariate
analysis, International Staging System (ISS) stage,
monoclonal immunoglobulin isotype, 1q21 gain
presence, and albumin, b2-microglobulin, and C-
reactive protein (CRP) levels were analyzed using
the Cox regression. P-values\.050 were considered
significant. Correlations between various chromo-
somal abnormalities were estimated by the Fisher’s
exact test. All statistical analyses were performed
using Statistica 7.1 software (StatSoft, Inc., Tulsa,
OK, USA, 2005).RESULTS
Incidence of Chromosomal Abnormalities in
MM Patients
1q21 gain (one or more additional signals from
1q21) was detected in 40.7% (37/91) MM patients.
Deletions del(13)(q14) and del(17)(p13) were detected
in 49.4% (44/89) and 14.9% (13/87), respectively.
Translocations t(4;14) and t(11;14) were detected in
23.7% (14/59) and in 19% (15/79) of patients, respec-
tively. Significant correlation between 1q21 gain and
del(13)(q14) presence was observed: del(13)(q14) was
present in 40.5% (15/37) of patients with 1q21 gain
versus 59.6% (31/52) of patients without 1q21 gain
(P 5 .089). del(17)(p13) nor t(4;14) nor t(11;14) were
not associated with the presence of 1q21 gain. The
data are summarized in Table 2.
Association between 1q21 Gain and Clinical and
Biologic Parameters
Patients with 1q21 gain had significantly higher
b2-microglobulin levels than did patients lacking
1q21 gain (P 5 .004). This understandably resulted
in a difference in ISS stage distribution between pa-
tients with versus without 1q21 gain. The majority of
Table 2. Association between 1q21 Gain Status and the
Presence of Other Genetic Abnormalities
1q21 Gain
Negative
1q21 Gain
Positive
P
(Fisher’s test)
Deletion of 13q14 (N 5 89) n 5 52 n 5 37 .089
Negative 31 (59.6%) 15 (40.5%)
Positive 21 (40.4%) 22 (59.5%)
Deletion of 17p13 (N 5 87) n 5 51 n 5 36 1.000
Negative 45 (88.2%) 32 (88.9%)
Positive 6 (11.8%) 4 (11.1%)
Translocation t(4;14) (N 5 59) n 5 35 n 5 24 .214
Negative 29 (82.9%) 16 (66.7%)
Positive 6 (17.1%) 8 (33.3%)
Translocation t(11;14) (N 5 79) n 5 48 n 5 31 .381
Negative 37 (77.1%) 27 (87.1%)
Positive 11 (22.9%) 4 (12.9%)
Biol Blood Marrow Transplant 16:548-554, 2010 551Gain of 1q21 in Multiple Myeloma1q21 gain-positive patients were in stages II (41.9%)
and III (38.7%), in contrast to 1q21 gain-negative pa-
tients, who were mostly in ISS stage I (55.3%) (P 5
.005). There was a trend toward difference between
1q21 gain positive versus negative patients in CRP
levels (5.8 versus 4.7 mg/L; P 5 .065), and there
were statistically significant differences in albumin
levels (37.1 versus 35.6 g/L; P 5 .038), and hemoglo-
bin levels (102.0 versus 116.5 g/L; P 5 .030). No dif-
ferences in patient age, sex, Durie-Salmon stage,
calcium levels, lactate dehydrogenase, or monoclonal
immunoglobulin levels were observed. Table 1 B sum-
marizes selected clinical and biologic parameters of
patients according to their 1q21 gain status.
Prognostic Relevance of 1q21 Gain for MM
Patients
All 67 randomized patients had evaluable results
for best treatment response after high-dose chemo-
therapy. Among patients with 1q21 gain (n 5 20),
ORR was 100.0% (20/20) with the following distribu-
tion: CR 20.0%, VGPR 40.0%, PR 40.0%. Among pa-
tients lacking 1q21 gain (n 5 47), 93.6% (44/47)
achieved ORR, including 21.3% CRs, 42.6% VGPRs,
and 29.8% PRs. However, the difference in ORR
between the 1q21 gain positive versus negative
patients was not statistically significant (P 5 .549).Table 3. Impact of 1q21 Gain on Treatment Response (ORR), Prog
Chromosomal
Abnormality N ORR P
1q21 gain positive 33 20/20 (100%) .549
1q21 gain negative 52 44/47 (93.6%)
del(13)(q14) positive 40 31/31 (100%) .240
del(13)(q14) negative 43 31/34 (91.2%)
del(17)(p13) positive 10 8/9 (88.9%) .263
del(17)(p13) negative 71 54/55 (98.2%)
t(4;14) positive 13 10/10 (100%) 1.000
t(4;14) negative 41 35/36 (97.2%)
t(11;14) positive 14 10/11 (90.9%) 1.474
t(11;14) negative 59 45/47 (95.7%)
ORR indicates overall response rate; PFS, progression-free survival; OS, overNo differences in ORR were observed between
patients with versus without del(13)(q14) (100.0%
versus 91.2%; P 5 .240), del(17)(p13) (88.9% versus
98.2%; P 5 .263), t(4;14) (100.0% versus 97.2%;
P 5 1.000), and t(11;14) (90.9% versus 95.7%;
P 5 .474). This suggests that the treatment response
of MM patients was not influenced by the presence
or absence of the studied chromosomal abnormalities
in plasma cells (Table 3).
We have also analyzed the prognostic impact of
each of the above chromosomal aberrations on PFS
and 4-year OS. Patients with 1q21 gain had signifi-
cantly shorter PFS than did patients lacking 1q21
gain (14.9 versus 27.4 months; P 5 .044) (Figure 1 A).
No significant differences inPFSbetweenpatients pos-
itive versus negative for other studied chromosomal ab-
errations were observed. Median PFS was 19.1 versus
27.6 months (P 5 .345) for del(13)(q14); 20.0 ver-
sus 23.4months (P5 .674) for del(17)(p13); 15.8 versus
28.6months (P5 .169) for t(4;14); and 27.0 versus 21.1
months (P5 .463)for t(11;14). Patients with 1q21 gain
had much worse 4-year OS than did patients lacking
1q21 gain (40.1% versus 76.2%;P\ .001) (Figure 1 B).
The presence or absence of other studied chromosomal
aberrations was not associated with statistically signif-
icant impact on OS. The 4-year OS probability for
del(13)(q14) was 56.9% versus 67.6% (P 5 .444);
52.5% versus 63.2% (P 5 .956) for del(17)(p13);
53.8% versus 72.0% (P 5 .156) for t(4;14); and
63.5% versus 61.8% (P5 .476) for t(11;14). All survival
data are summarized in Table 3.DISCUSSION
MM is a plasma cell malignancy characterized by
a marked karyotypic instability [27]. Unfortunately,
classical cytogenetic analyses are hampered by the
low percentage of plasma cells present in BM biopsy,
low proliferation activity of plasma cells in vitro, and
the predominance of normal karyotype, mostly origi-
nating from normal hematopoietic cells in the BM as-
pirate. Banding techniques have been reported to beression-Free Survival (PFS), and 4-Year Overall Survival (OS)
PFS Median
(Months) P 4-Year OS P
14.9 .044 40.1% <.001
27.4 76.2%
19.1 .345 56.9% .444
27.6 67.6%
20.0 .674 52.5% .956
23.4 63.2%
15.8 .169 53.8% .156
28.6 72.0%
27.0 .463 63.5% .476
21.1 61.8%
all survival.
Figure 1. Kaplan-Meier survival curves. PFS in relation to 1q21 gain (A) and OS in relation to 1q21 gain (B).
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hand, interphase FISH is a quick and efficient method
able to detect single specific aberrations in plasma cells
in as many as 90% of cases [19]. RB1 deletion, TP53
deletion, and translocation t(4;14) have been described
as adverse risk factors in MM. Gain of 1q21 region is 1
of the most common recurrent chromosomal abnor-
malities in MM and has been reported to be associated
with shorter median survival and with disease progres-
sion [5,29].
Few studies have evaluated the prognostic rele-
vance of 1q21 gain and the association of this chromo-
somal abnormality with disease progression or
resistance to treatment in newly diagnosed or relapsed
MM since the first report published by Shaughnessy in
2005 [14]. The same group has shown that testing for
1q21 gain can provide valuable prognostic information
[11]. Our study confirms some of the findings reported
previously by Chang et al. [10].
The most recent studies reported not only an unfa-
vorable prognostic impact of gain/amplification of
1q21, but also revealed a strong impact of the deletion
of 1 p chromosomal locus (associated with reduced
PFS as well as OS) in MM patients treated with
high-dose chemotherapy [30,31]. Moreover, gene ex-
pression profiling revealed altered expression of genes
mapping to both arms of chromosome 1 and identified
high-risk group of patients [32].
In our study, the prognostic impact of 1q21 gain
detected by interphase FISH was assessed in a series
of 91 myeloma patients registered in CMG2002 clin-
ical trial. Gain of 1q21 was identified in 40.7% of all
91 cases. This result is consistent with previously
published reports that found 1q21 gain in 30% to
50% of MM cases [10,11]. Deletion of 13q14 was
the most frequent aberration (49.4%) in our study,
whereas del(17)(p13) was the rarest (14.9%). The in-
cidences of the 2 IgH translocations t(4;14) and
t(11;14) in our study were somewhat higher than
those reported by the Mayo Clinic group and by
the French group [6,20]. The reason for relatively
high incidence of translocation t(4;14) may havebeen caused by the small number of patients in the
cohort of 91 patients evaluated for 1q21 gain. This
is supported by our analysis of all 208 patients en-
rolled in the CMG2002 trial, which has shown
a much lower incidence of t(4;14) of 15.8%. We
have found an association between the presence of
1q21 gain and del(13)(q14). On the other hand, no
association between 1q21 gain and the translocations
t(4;14) or t(11;14) and del(17)(p13) was observed.
The overall response rate was not influenced by the
presence or absence of any of the studied chromo-
somal abnormalities. Moreover, we have observed
that of all evaluated chromosomal changes, only
1q21 gain was significantly associated with shorter
PFS and worse 4-year OS. The presence of 1q21
gain in plasma cells of MM patients reduced PFS
median by about 1 year. In addition, the presence
of 1q21 gain also adversely decreased the probability
of 4-year OS. Although 1q21 gain was associated
with del(13)(q14), 1q21 gain can be considered an in-
dependent prognostic factor because no prognostic
impact on either OS or PFS was observed for
del(13)(q14) if present as a sole chromosomal abnor-
mality. At the present time, prognostic impact of
del(13)(q14) remains controversial, especially when
the deletion is detected as an isolated chromosomal
abnormality [18]. Our additional unpublished results
have shown poor survival of patients who have 1q21
gain in combination with any other of the studied ab-
errations except t(11;14) (data not shown). This is in
line with the hypothesis of separate clonal evolution
of t(11;14) positive MM [5].
A limited analysis was that patients were treated ac-
cording to a protocol designed over 8 years ago, so no
new drugs were used in the CMG2002 study. Several
research groups have reported that novel agents such
as bortezomib and lenalidomide are able to overcome
the unfavorable impact of cytogenetic abnormalities
in MM patients. In relapsed/refractory MM patients
bortezomib-based regimens may overcome the ad-
verse prognostic effect of del(13)(q14) and t(4;14)
[33,34]. In the VISTA clinical trial, newly diagnosed
Biol Blood Marrow Transplant 16:548-554, 2010 553Gain of 1q21 in Multiple Myelomahigh-risk patients with t(4;14), t(14;16), and
del(17)(p13) had similar prognosis as low-risk patients
[35]. Conclusive data on the prognostic impact of
chromosomal abnormalities in younger patients
treated with autologous transplantation who receive
bortezomib during induction and/or consolidation
phase of the therapy are not yet available. Our knowl-
edge about lenalidomide is even more limited. Lenali-
domide is an effective therapy for relapsed/refractory
MM patients, but it seems ineffective in patients with
del(17)(p13) [36,37]. Lower response rate in
del(17)(p13) group of patients has been observed
[36]. In heavily pretreated relapsed/refractory MM
patients treated with lenalidomide/dexamethasone
combination, the presence of del(13), progression on
thalidomide (ie, prior thalidomide use), and hemoglo-
bin levels $10 g/dL were identified as independent
predictors of reduced PFS [38].
Very limited data is available on the efficacy of
novel antimyeloma agents in untreatedMMwith cyto-
genetic abnormalities, including gain 1q21. Pilot data
reported by Chang et al. in 2006 [39] show similar me-
dian PFS and OS for 1q21 gain-positive and -negative
relapsed/refractory MM patients, suggesting that bor-
tezomib probably is able to overcome the unfavorable
impact of this abnormality. This agrees with our un-
published results. However, all these findings need to
be confirmed and validated as part of prospective ran-
domized clinical trials evaluating both uniform and
modern combination therapy.
We note in particular that as many as 35.1% of
patients with 1q21 gain were not randomized to post-
transplant maintenance/consolidation therapy because
of disease progression or death. In contrast, in patients
lacking 1q21 gain, 9.3% were not randomized because
of disease progression or death. This further supports
our observation that 1q21 gain defines a prognostically
unfavorable group. However, prospective studies on
larger patient cohorts are required for confirmation
of the role of 1q21 gain in MM, especially in patients
treated with new drugs such as lenalidomide and
bortezomib.ACKNOWLEDGMENTS
The authors thank all participating members of
Czech Myeloma Group as well as all patients, their
caregivers, and referring physicians for making this
work possible. This study was supported by research
grant LC06027 from the Masaryk University, Brno,
Czech Republic, by grants MSM0021622415,
MSM0021622434, and MSM0021620808 from the
Ministry of Education, Czech Republic, and by grants
MZOVFN2005, NR/9317-3, NR/8183-4 and
NS10207-3/2009 from the Internal Grant Agency
(IGA) of the Ministry of Health, Czech Republic.Financial disclosure: The authors have nothing to
disclose.REFERENCES
1. Attal M, Harousseau JL, Facon T, et al. Single versus double au-
tologous stem-cell transplantation formultiplemyeloma.NEngl
J Med. 2003;349:2495-2502.
2. Moreau P, Hullin C, Garban F, et al. Tandem autologous stem
cell transplantation in high-risk de novomultiple myeloma: final
results of the prospective and randomized IFM 99-04 protocol.
Blood. 2006;107:397-403.
3. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and
prednisone chemotherapy plus thalidomide compared with mel-
phalan and prednisone alone in elderly patients with multiple
myeloma: randomised controlled trial. Lancet. 2006;367:
825-831.
4. SanMiguel JF, SchlagR,KhuagevaN, et al.MMY-3002: a phase
3 study comparing bortezomib-melphalan-prednisone (VMP)
with melphalan-prednisone (MP) in newly diagnosed multiple
myeloma. Blood. 2007;110. Abstract 76.
5. Cremer FW, Bila J, Buck I, et al. Delineation of distinct sub-
groups of multiple myeloma and a model for clonal evolution
based on interphase cytogenetics. Genes Chromosomes Cancer.
2005;44:194-203.
6. Fonseca R, Blood E, RueM, et al. Clinical and biologic implica-
tions of recurrent genomic aberrations in myeloma. Blood. 2003;
101:4569-4575.
7. Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic
findings in 200 patients with multiple myeloma. Cancer Genet
Cytogenet. 1995;82:41-49.
8. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B. Jump-
ing translocations of chromosome 1q in multiple myeloma:
evidence for a mechanism involving decondensation of pericen-
tromeric heterochromatin. Blood. 1998;91:1732-1741.
9. Sawyer JR, Tricot G, Lukacs JL, et al. Genomic instability in
multiple myeloma: evidence for jumping segmental duplications
of chromosome arm 1q. Genes Chromosomes Cancer. 2005;42:
95-106.
10. Chang H, Qi X, Trieu Y, et al. Multiple myeloma patients with
CKS1B gene amplification have a shorter progression-free sur-
vival post-autologous stem cell transplantation. Br J Haematol.
2006;135:486-491.
11. Hanamura I, Stewart JP, Huang Y, et al. Frequent gain of chro-
mosome band 1q21 in plasma-cell dyscrasias detected by fluo-
rescence in situ hybridization: incidence increases from
MGUS to relapsed myeloma and is related to prognosis and dis-
ease progression following tandem stem-cell transplantation.
Blood. 2006;108:1724-1732.
12. Spruck C, Strohmaier H,WatsonM, et al. A CDK-independent
function of mammalian Cks1: targeting of SCF(Skp2) to the
CDK inhibitor p27Kip1. Mol Cell. 2001;7:639-650.
13. Ganoth D, Bornstein G, Ko TK, et al. The cell-cycle regulatory
protein Cks1 is required for SCF(Skp2)-mediated ubiquitinyla-
tion of p27. Nat Cell Biol. 2001;3:321-324.
14. Shaughnessy J. Amplification and overexpression of CKS1B at
chromosome band 1q21 is associated with reduced levels of
p27Kip1 and an aggressive clinical course in multiple myeloma.
Hematology. 2005;10:117-126.
15. Inoue J, Otsuki T, Hirasawa A, et al. Overexpression of PDZK1
within the 1q12-q22 amplicon is likely to be associated with
drug-resistance phenotype in multiple myeloma. Am J Pathol.
2004;165:71-81.
16. Fonseca R,HarringtonD,OkenMM, et al. Biological and prog-
nostic significance of interphase fluorescence in situ hybridiza-
tion detection of chromosome 13 abnormalities (delta13) in
multiple myeloma: an Eastern Cooperative Oncology Group
Study. Cancer Res. 2002;62:715-720.
17. ChangH,Qi C, Yi QL, ReeceD, Stewart AK. p53 gene deletion
detected by fluorescence in situ hybridization is an adverse
554 Biol Blood Marrow Transplant 16:548-554, 2010P. Nemec et al.prognostic factor for patients with multiple myeloma following
autologous stem cell transplantation. Blood. 2005;105:358-360.
18. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic
and biological implications of genetic abnormalities in multiple
myeloma undergoing autologous stem cell transplantation:
t(4;14) is the most relevant adverse prognostic factor, whereas
RB deletion as a unique abnormality is not associated with ad-
verse prognosis. Leukemia. 2007;21:143-150.
19. Avet-Loiseau H, Facon T, Grosbois B, et al. Oncogenesis of
multiple myeloma: 14q32 and 13q chromosomal abnormalities
are not randomly distributed, but correlate with natural history,
immunological features, and clinical presentation. Blood. 2002;
99:2185-2191.
20. Avet-LoiseauH, AttalM,Moreau P, et al. Genetic abnormalities
and survival in multiple myeloma: the experience of the Inter-
groupe Francophone du Myelome. Blood. 2007;109:3489-3495.
21. Hajek R, Spicka I, Scudla V, et al. Consolidation therapy based
on conventional chemotherapy and corticoids do not provide
therapeutic advantage for newly diagnosed patients after autolo-
gous transplantation. Blood. 2007;110. Abstract 531.
22. Ahmann GJ, Jalal SM, Juneau AL, et al. A novel three-color,
clone-specific fluorescence in situ hybridization procedure for
monoclonal gammopathies. Cancer Genet Cytogenet. 1998;101:
7-11.
23. UCSC Genome Bioinformatics. Available at: http://genome.ucs-
c.edu/cgi-bin/hgGateway. Accessed November 20, 2007.
24. American Society of Medial Genetics: Standards and Guidelines
for Clinical Genetics Laboratories. Available at: http://
www.acmg.net/Pages/ACMG_Activities/stds-2002/e.htm. Ac-
cessed November 20, 2007.
25. Ross FM, Avet-Loiseau H, Drach J, Hernandez Rivas JM,
Liebisch P. European myeloma network recommendations for
FISH in myeloma. Haematologica. 2007;92. Abstract 114.
26. Durie BG, Harousseau JL, Miguel JS, et al. International uni-
form response criteria for multiple myeloma. Leukemia. 2006;
20:1467-1473.
27. Seidl S, KaufmannH,Drach J.New insights into the pathophys-
iology of multiple myeloma. Lancet Oncol. 2003;4:557-564.
28. Smadja NV, Bastard C, Brigaudeau C, et al. Groupe Franc¸ais
de Cytogenetique Hematologique. Hypodiploidy is a major
prognostic factor in multiple myeloma. Blood. 2001;98:
2229-2238.
29. Fonseca R, Van Wier SA, Chng WJ, et al. Prognostic value of
chromosome 1q21 gain by fluorescent in situ hybridizationand increase CKS1B expression in myeloma. Leukemia. 2006;
20:2034-2040.
30. QazilbashMH, Saliba RM, Ahmed B, et al. Deletion of the short
arm of chromosome 1 (del 1p) is a strong predictor of poor out-
come in myeloma patients undergoing an autotransplant. Biol
Blood Marrow Transplant. 2007;13:1066-1072.
31. Chang H, Qi X, Jiang A, Xu W, Young T, Reece D. 1p21 dele-
tions are strongly associated with 1q21 gains and are an indepen-
dent adverse prognostic factor for the outcome of high-dose
chemotherapy in patients with multiple myeloma. Bone Marrow
Transplant. 2009 [Epub ahead of print].
32. Shaughnessy JD Jr., Zhan F, Burington BE, et al. A validated
gene expression model of high-risk multiple myeloma is defined
by deregulated expression of genes mapping to chromosome 1.
Blood. 2007;109:2276-2284.
33. Richardson PG, Barlogie B, Berenson J, et al. http://
www.ncbi.nlm.nih.gov/pubmed?term5%22Singhal%20S%22%
5BAuthor%5D&itool5EntrezSystem2.PEntrez.Pubmed.Pub
med_ResultsPanel.Pubmed_RVAbstract Clinical factors predic-
tive of outcome with bortezomib in patients with relapsed, re-
fractory multiple myeloma. Blood. 2005;106:2977–2981.
34. Jagannath S, Richardson PG, Sonneveld P, et al. Bortezomib ap-
pears to overcome the poor prognosis conferred by chromosome
13 deletion in phase 2 and 3 trials. Leukemia. 2007;21:151-157.
35. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus
melphalan and prednisone for initial treatment of multiple my-
eloma. N Engl J Med. 2008;359:906-917.
36. Reece D, Song KW, Fu T, et al. Influence of cytogenetics in pa-
tients with relapsed or refractory multiple myeloma treated with
lenalidomide plus dexamethasone: adverse effect of deletion
17p13. Blood. 2009;114:522-525.
37. Bahlis NJ, SongK, Trieu Y, et al. Lenalidomide overcomes poor
prognosis conferred by del13q and t(4;14) but not del17p13 in
multiple myeloma: results of the Canadian MM016 Trial. Blood.
2007;110. Abstract 3597.
38. Avet-LoiseauH, Soulier J, Fermand JP, et al. Impact of chromo-
somal abnormalities Del(13), T(4;14), and Del(17p) and prior
treatment on outcomes in patients with relapsed or refractory
multiple myeloma treated with lenalidomide. Blood. 2008;112.
Abstract 3685.
39. Chang H, Trieu Y, Qi X, Xu W, Stewart KA, Reece D. Borte-
zomib therapy response is independent of cytogenetic abnor-
malities in relapsed/refractory multiple myeloma. Leuk Res.
2007;31:779-782.
